Stay updated on Cabozantinib and Immunotherapy in Genitourinary Tumors Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib and Immunotherapy in Genitourinary Tumors Clinical Trial page.

Latest updates to the Cabozantinib and Immunotherapy in Genitourinary Tumors Clinical Trial page
- Check4 days agoChange DetectedAdded updates dated 2026-04-02 and 2026-04-03, and removed updates dated 2026-03-26 and 2026-03-27.SummaryDifference0.1%

- Check11 days agoChange DetectedAdditions on 2026-03-26 and 2026-03-27 introduce Urinary bladder small cell neuroendocrine carcinoma as a listed condition; deletions on 2026-03-19 and 2026-03-20 remove two previously listed items, updating the study's documented condition scope.SummaryDifference0.1%

- Check19 days agoChange DetectedPage revision updated to v3.5.0; prior revision v3.4.3 was removed.SummaryDifference0.1%

- Check26 days agoChange DetectedAdministrative updates to the study record: new update dates posted on 2026-03-12 and 2026-03-13, replacing earlier dates 2026-03-05 and 2026-03-06.SummaryDifference0.1%

- Check33 days agoChange DetectedAdded entries for 2026-03-05 and 2026-03-06 with Revision: v3.4.3; older 2025 entries and Revision: v3.4.2 were removed.SummaryDifference0.2%

- Check55 days agoChange DetectedRevision tag updated from v3.4.1 to v3.4.2; no visible changes to page content.SummaryDifference0.0%

Stay in the know with updates to Cabozantinib and Immunotherapy in Genitourinary Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib and Immunotherapy in Genitourinary Tumors Clinical Trial page.